Alembic gets USFDA nod for generic drug for skin condition

Alembic Pharmaceuticals has secured USFDA approval for its generic Tretinoin Cream USP (0.025%), a treatment for acne vulgaris. This ANDA is therapeutically equivalent to Bausch Health US, LLC's Retin-A Cream. The market size for Tretinoin cream USP (0.025%) is estimated at USD 94 million for the twelve months ending June 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQjfEAB
via IFTTT